We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Dynavax Technologies Corp | NASDAQ:DVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.17% | 11.74 | 11.46 | 11.98 | 12.06 | 11.71 | 11.87 | 1,817,398 | 01:00:00 |
From May 2019 to May 2024
The presentation will be webcast and may be accessed through the “Events & Presentations” page on the “investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.
About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndtnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations Advisory Solutionsderek.cole@IRadvisory.com
1 Year Dynavax Technologies Chart |
1 Month Dynavax Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
